Copyright © 2025 Authors retain the copyright of this article. This article is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

@article{163204,
        author = {Cheekati Reshma and PASHAM VENKANNA},
        title = {Formulation development, in vitro and in vivo studies of eprosartan mesylate loaded solid lipid nanoparticles for improved bioavailability},
        journal = {International Journal of Innovative Research in Technology},
        year = {},
        volume = {10},
        number = {11},
        pages = {812-817},
        issn = {2349-6002},
        url = {https://ijirt.org/article?manuscript=163204},
        abstract = {Eprosartan mesylate (EM) is an angiotensin receptor blocker (ARB) used to treat hypertension. It has an oral bioavailability of 13%. The work intends to evolve eprosartan mesylate of solid lipid nanoparticles (EM-SLNs) to enhance bioavailability. EM-SLNs were developed using hot homogenization followed by ultrasonication by using lipids dynasan 118, dynasan 116, and dynasan 114. The optimized formulation EM-SLNs (F7) showed the particle size is 151.3 nm, poly disperse index (PDI) shows 0.210 and zeta potential (ZP) values were -31.74mV, which indicated the stability of developed EM-SLNs. The entrapment efficiency (EE) was found to be 85.10%. EM-SLNs were established as likely spherical with a lustrous exterior, as making do with scanning electron microscope (SEM). Relative bioavailability of the optimized EM-SLNs (F7) was increased by 1.84 times, differentiated with the coarse suspension of pure drug.},
        keywords = {Bioavailability, solid lipid nanoparticles, homogenization and eprosartan mesylate},
        month = {},
        }